Baidu
map

Neurology: 卒中护理综合系统可降低卒中患者30天死亡率

2016-04-10 MedSci MedSci原创

背景:评估加拿大卒中护理综合系统与卒中病死率之间的相关性。方法:加拿大的研究者应用加拿大健康信息出院摘要数据库,识别2003 / 2004年到2013 / 2014年这11个财政年度,除魁北克省入院到所有急性护理医院的卒中/ TIA患者。研究者应用改良Poisson回归模型,校正年龄,性别、卒中类型、合并症,出院年份,计算与无卒中患者相比,卒中患者30天的住院死亡率的aIRR。研究者对2009年和

背景:评估加拿大卒中护理综合系统与卒中病死率之间的相关性。

方法:加拿大的研究者应用加拿大健康信息出院摘要数据库,识别2003 / 2004年到2013 / 2014年这11个财政年度,除魁北克省入院到所有急性护理医院的卒中/ TIA患者。研究者应用改良Poisson回归模型,校正年龄,性别、卒中类型、合并症,出院年份,计算与无卒中患者相比,卒中患者30天的住院死亡率的aIRR。研究者对2009年和2013年加拿大医院的卒中护理资源进行调查,并比较有无综合系统省份的资源。

结果:共319972例患者因卒中/短暂性脑缺血发作(TIA)入院。有卒中系统的省份,卒中30天死亡率由2003 /2004年度的15.8%下降到2012 /2013年度的12.7%,然而,没有卒中系统的省份,卒中30天死亡率仍为14.5%。从2009/2010年度开始,与无卒中系统的省份相比,有卒中系统的省份相对死亡率明显下降,2011/2012年度,2012/2013年度、2013/2014年度,aIRR值维持在0.85(95%CI 0.79-0.92)。调查显示,有卒中系统的省份更可能在卒中单元进行护理治疗,并且能够及时的进行卒中预防及远程卒中服务。

结论:在这项回顾性研究中,卒中护理综合系统的实施与卒中后死亡率的降低有关。

原文出处:

Ganesh A, Lindsay P, et al. Integrated systems of stroke care and reduction in 30-day mortality: A retrospective analysis. Neurology. 2016 Mar 8.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1977761, encodeId=87b519e7761f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Apr 24 12:06:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999675, encodeId=006b19996e52e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Feb 17 01:06:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720104, encodeId=95981e2010497, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 24 12:06:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78101, encodeId=1323e810173, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78102, encodeId=8fcbe8102c1, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-24 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1977761, encodeId=87b519e7761f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Apr 24 12:06:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999675, encodeId=006b19996e52e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Feb 17 01:06:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720104, encodeId=95981e2010497, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 24 12:06:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78101, encodeId=1323e810173, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78102, encodeId=8fcbe8102c1, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2017-02-17 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1977761, encodeId=87b519e7761f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Apr 24 12:06:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999675, encodeId=006b19996e52e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Feb 17 01:06:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720104, encodeId=95981e2010497, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 24 12:06:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78101, encodeId=1323e810173, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78102, encodeId=8fcbe8102c1, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1977761, encodeId=87b519e7761f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Apr 24 12:06:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999675, encodeId=006b19996e52e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Feb 17 01:06:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720104, encodeId=95981e2010497, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 24 12:06:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78101, encodeId=1323e810173, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78102, encodeId=8fcbe8102c1, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-14 李继凯

    文章不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1977761, encodeId=87b519e7761f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Apr 24 12:06:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999675, encodeId=006b19996e52e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Feb 17 01:06:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720104, encodeId=95981e2010497, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Nov 24 12:06:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78101, encodeId=1323e810173, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78102, encodeId=8fcbe8102c1, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-14 李继凯

    值得学习

    0

相关资讯

Sci Rep:CEE治疗可增加台湾更年期女性发生房颤的风险

激素替代疗法(HRT)与血管疾病风险相关。先前研究显示:心房颤动(AF),血管事件和不同的HRTs,包括雌二醇和共轭雌激素(CEE)相关性的研究存在争议。因此,研究者进行回顾性队列研究,以调查相关性。台湾的研究者从国家健康保险研究数据库(1998-2008)中招募首次确诊为更年期的女性患者(>45岁)。应用Cox回归分析评估应用雌二醇或CEE治疗后,受试者新发房颤、卒中和主要不良心脏事件(MACE

Neurology:应用他汀类药物可降低卒中后出血的风险

目标:评估急性缺血性卒中(AIS)发生前后应用他汀类药物治疗对急性脑出血(ICH)的风险,急性后期ICH的风险及90天死亡率的影响。方法:研究者从虚拟国际卒中试验档案(VISTA)这一国际资料库的临床试验数据中选取数据。应用倾向评分匹配,研究者回顾性比较先前应用他汀治疗的患者和AIS后3天开始应用他汀类治疗的患者。主要预后为急性症状型ICH(sICH),任何急性ICH,急性后期ICH和随访3个月的

Cerebrovasc Dis:穿支动脉粥样硬化疾病:一个具有临床意义,但还未经检验的概念

在1989年,Louis Caplan第一次使用了穿支动脉粥样硬化疾病(BAD)这一术语来描述大脑深穿支动脉起始部分的狭窄或闭塞,与小动脉粥样硬化或开口处斑块相关,可以导致内囊或者脑桥的小梗死。数十年来BAD仍然是一个未被研究的概念。最近数年,高分辨率磁共振技术的与日扩散带来了对BAD争论的新的关注。我们回顾了和BAD相关的卒中的临床研究,来发现一个BAD的明确定义,以及临床及影像特点报道一致性的

ACC 2016:GlycA水平可预测民众患心血管疾病和卒中风险

2016年美国心脏病学会科学会议提出,如果机体动脉血液中含有高水平炎症标记物,则高水平高密度脂蛋白不能保护人们免受心脏病的困扰。动脉壁的炎症会增加民众出现心脏病或卒中的风险,因为它增加了动脉壁斑块破裂的风险。动脉斑块一旦破裂,则会导致血栓的形成和血管的闭塞。 胆固醇是一种脂肪物质。人体需要适量的胆固醇,但是如果胆固醇含量太高,它可以聚集在动脉,从而导致民众出现心脏病和卒中。低密度脂蛋白(LDL)—

Int J Stroke:通过高分辨率血管壁MRI发现颅内斑块增强预测卒中复发

颅内动脉粥样硬化和频繁的卒中复发相关。高分辨率血管壁磁共振可以提供关于动脉粥样硬化易损性的信息。研究目标:我们对有颅内动脉粥样硬化的病人实施高分辨率磁共振来判断管壁斑块的性质可以预测未来卒中的复发。研究方法:在2011年7月到2013年6月,有症状性颅内粥样硬化的急性卒中的 病人被前瞻性入组,并对其相关动脉进行3T高分辨率磁共振检查。斑块增强 可以从注射钆剂后T1的增强图像判断。急性事件

Int J Cardiol:识别卒中患者发生房颤的模型

背景和目的:急性脑卒中患者发生房颤的风险较高。这篇研究的目的旨在构建一个模型,可以预测急性缺血性卒中患者,房颤的存在,并且验证此模型。方法:研究者参与实验的两个医院中,收集基于医院的卒中登记记录,研究者选取症状开始24h内的患者。应用1355个急性缺血性卒中患者的数据,构建预测房颤的存在的模型,并且统计可能发生房颤的概率。根据房颤的发生可能,将患者分为低危,中危和高危组。调查并验证急性缺血性卒中患

Baidu
map
Baidu
map
Baidu
map